Mayo Clinic, Janssen-backed venture gets FDA OK for pulmonary hypertension AI algorithm
Related Articles
Way of Diagnosing PH in Common Heart Test Gets FDA Support
Pulmonary Hypertension News: Anumana’s electrocardiogram (ECG)-based algorithm for the early detection of pulmonary hypertension (PH) has been designated a breakthrough device by the U.S. Food and Drug Administration (FDA). The…May 26, 2022
Mayo Clinic launches two tech companies
Modern Healthcare: One of the companies, Anumana, is seeking clearance from the Food and Drug Administration to market an artificial-intelligence tool to detect heart conditions.April 13, 2021
Anumana wins FDA breakthrough nod for AI algorithm that detects pulmonary hypertension
Mass Device: Anumana announced today that it received FDA breakthrough device designation for its pulmonary hypertension (PH) early detection algorithm. Cambridge, Massachusetts-based Anumana, formed by Mayo Clinic and nference and launched in…May 23, 2022
Anumana Acquires NeuTrace, Establishing a Comprehensive Electrophysiology Deep-Learning Development Platform and Product Pipeline
Anumana acquires NeuTrace, a medical technology company advancing novel in-procedure AI applications for electrophysiology (EP)November 07, 2022